PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-27.92%
Negative net income growth while TRAW stands at 18.39%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
3.10%
Some D&A expansion while TRAW is negative at -25.00%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
No Data
No Data available this quarter, please select a different quarter.
-10.46%
Negative yoy SBC while TRAW is 0.00%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
292.72%
Slight usage while TRAW is negative at -266.20%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
215.28%
A yoy AP increase while TRAW is negative at -179.47%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
292.72%
Some yoy usage while TRAW is negative at -803.85%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
-67.58%
Negative yoy while TRAW is 86.31%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-21.90%
Negative yoy CFO while TRAW is 0.93%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
-11.48%
Negative yoy CapEx while TRAW is 0.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-11.48%
We reduce yoy invests while TRAW stands at 0.00%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
No Data
No Data available this quarter, please select a different quarter.
-59.52%
Negative yoy issuance while TRAW is 284814.29%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.